Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy
Lung Cancer, Sarcoidosis, Interstitial Pneumonia
About this trial
This is an interventional treatment trial for Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Subjects undergoing a planned, ambulatory flexible bronchoscopy (for transbronchial lung biopsy or endobronchial ultrasound guided procedures) in moderate sedation, aged between 18 and 85 years
Exclusion Criteria:
- History of solid organ or bone marrow transplantation with the use of an immunosuppressive therapy
- HIV infection on anti-retroviral therapy
- Alcohol consumption more than two standard drinks per day
- Use of illicit drugs (heroin, opiates)
- Any contraindication to use propofol for sedation (e.g. allergy)
- Body mass index > 35 kg/m2
- Mental disorder preventing appropriate judgment concerning study participation
- Missing written patient's informed consent
Sites / Locations
- University Hospital Zurich
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Fractionated propofol administration
Propofol-TCI
Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response. Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy
Flexible bronchoscopy in moderate sedation with TCI propofol perfusor: Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation. Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively.